Live Now Button (3)

Unlocking Future Insights in Biologics Research & Development

24 - 25 March 2026
QEII Centre, London, UK

Now: Afternoon Sessions

Follow along live as industry leaders unveil the latest advancements in biomedicine. 

15:05

Panel Discussion: NextGen Vaccine Strategies To Advance Cancer Treatment
Moderator: ANTONIO POSTIGO, Chief Scientific Officer, Stratosvir Ltd

Panel Discussion: The Next Chapter Of Oligonucleotide Delivery
Moderator: STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, DMPK, GSK

Empowering Antibody Engineering – Highlights From Early Beginnings Of Using AI-Based Tools For Optimization & Functional Engineering Of Antibody Candidates
BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck

Panel Discussion: Mixed Modalities: Addressing The Challenges & Opportunities To Drug The Undruggable

Multivalent Ligand Design To Selectively Bind Proteins
NATHAN ALVES, Research Director, Indiana University School Of Medicine

15:30

Cyclotides As Ultra-Stable Combinatorial Display Platforms For Peptide-Based Drug Discovery
DAVID CRAIK, Professor, University Of Queensland

Enhancing Biologics Lead Optimisation By Combining Affinity Prediction Methods & Active Learning
OWEN VICKERY, Associate Principal Scientist, AstraZeneca

InSiDe Out: In Silico Developability Screening At AstraZeneca, Impact To Date & Future Direction
ISABELLE SERMADIRAS, Associate Principal Scientist, AstraZeneca

15:55

Unveiling Hidden Targets: AI-Driven Discovery Of Therapeutic Cancer Antigens From The Dark Genome
CHRISTIAN GARDE, Director, Evaxion

The Identification Of Cyclic Peptide Metabolic Soft Spots By Isotope-Labelled Reductive Dimethylation & Leveraging High-Resolution Ion Mobility-Mass Spectrometry
MARIA FAWAZ, Associate Principal Scientist, MS

Using The Very Small To Tackle The Very Large – Our Journey From Concept To Clinic
IJEOMA UCHEGBU, Professor Of Pharmaceutical Nanoscience, University College London

First-In-Class Site-Directed Targeted soloMER Drug Conjugate For Autoimmune Inflammation
OBINNA UBAH, Principal Scientist, Elasmogen

Rationalising MABs Developability Testing
DAVID BROCKWELL, Professor, University Of Leeds

16:20

Development & Qualification Of A Cell-Based Potency Assay For Two Novel DNA Cancer Vaccine
ELISA MARELLI, Research Scientist, Scancell

Short Novel Peptides As Chelating Agents For Metal-Related Diseases
MICHAL SHOSHAN, Founder & Chief Executive Officer, metaLead Therapeutic

Purification Of Oligonucleotides & Their Conjugates For Progressing Early Drug Discovery Projects & The Chromatographic Challenges With Oligonucleotide G-rich Sequences
YIPING WU, Senior Scientist, AstraZeneca

Removing Biological Roadblocks To Better Treatments: The Power Of Nanofitin-Enhanced Biologics
MATHIEU CINIER, Scientific Director, Affilogi

Share Your NextGen Biomed Moments

We'd love to see your favourite moments and photos on social media! Use the hashtags #NextGenBiomed2025 and #NGB2025, and tag our official accounts below.

Look Back at NextGen Biomed 2025

From beginning to end, NextGen Biomed showcased the remarkable innovation within our community.

The event featured engaging content and discussions across the entire value chain—from antibody engineering advancements to sustainable practices in TIDES chemistry—underscoring our collective commitment to advancing immunotherapy and biologics R&D.

Explore the NextGen Biomed 2026 Programme

Antibody Society

NextGen Biomed 2025 was supported by our
Scientific Programme Partner The Antibody Society

NextGen Biomed Square

About

Discover more about our ecosystem of channels for the biologics R&D community

Attend Image

Attend

Be part of the new wave of Biomed R&D innovation

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers

Whats On Image

What's On

Explore dynamic panels, engaging roundtables, and hands-on workshops

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow, Lundbeck; Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Presentation: What Does The Future Hold For Orally Available Peptides?

Presented by: Immanuel Lerner, Chief Executive Officer, 
Pepticom

Oligonucleotides
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery

Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK
Panellists include 

Saul Martinez Montero, Senior Director, RNA Therapeutics, Dyne Therapeutics
Morten Lindow, RNAHub Founder & Mission Lead, Roche
Sritama Bose, Head Of Chemistry Research & Innovation, NATA
Fazel Shabanpoor, Co-Founder & Chief Scientific Officer & Associate Professor & Head Of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute

 

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How Vaccines & Immunotherapy Strategies: Converging Pathways For Preventing Or Treating Chronic Diseases

Presented by: Daniel Larocque, Innovation Lead, Innovation & Emerging Science, Sanofi

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful fireside chats, to an exclusive gala dinner at London's Science Museum. Discover the moments that will transform your NextGen Biomed experience. 

NextGen Biomed 2026 Speakers:

Anders Gabrielsen
Vice President & Head of Global Clinical Development,
Ribocure Pharmaceuticals
Anna Perdrix
Chief Executive Officer,
Sixfold Bioscience
Annelise Vuidepot, PhD
Senior Vice President & Chief Technical Officer - Head of Pipeline & Platform Research and UK site Head,
Immunocore
Caroline Jane Barelle
Chief Executive Officer,
Elasmogen Ltd
Chris Herring
Vice President TCR-T,
T-Therpautics
Christian Mueller
Chief Development Officer,
Immutep
Hannah Bolt
Head of Peptide Discovery, Director,
AstraZeneca
Karen Silence
Vice President, Head of Preclinical Product Development ,
Argenx
Lilly Wollman
Chief Executive Officer,
Synteny
Maria Liljevald
Head of Global Regulatory Affairs,
Ribocure Pharmaceuticals
Paul Kellam
Chief Scientific Officer,
RQ Bio
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Agnieszka Lewandowska
Associate Director Analytical Development,
Immunocore
Alessandra Tolomelli
Associate Professor,
Alma Mater Studiorum – Università di Bologna
Allan Bradley
Founder, Director and Chief Scientific Officer,
T-Therapeutics
Anders Dahlen
Director, Oligo Chemistry Team,
AstraZeneca
Andreas Hollenstein
Principal Scientist, Immunosafety,
Roche
Andrew Feilden
Senior Director Analytical Science,
Bicycle Therapeutics
Angus Sinclair
Chief Scientific Officer,
LabGenius Therapeutics
Annabelle Biscans
Director, Oligonucleotide Chemistry,
AstraZeneca
Annabelle Herrington-Symes, PhD
Biologics Discovery & Development Senior Scientist,
LifeArc
Beth Wensley
Principal Scientist - Protein and Analytical Sciences,
LifeArc
Birgit Piater
Head of Laboratory, Antibody Drug Conjugates,
Merck US
Brenda Iglesias
Associate Director, Strategic Partnerships,
GSK
Cecile Brocard
Director Downstream Development,
Boehringer Ingelheim
Charles Johannes
Co-founder,
FogPharma
Christopher Lloyd
Director,
AstraZeneca
Colette Johnston
VP Product Pipeline,
Enara Bio
Daniel Fleischanderl
Director Upstream Development,
Takeda
Daniëlle van Wijk
Principal Scientist,
Byondis bv
David Rodríguez
Principal Modelling Scientist,
Novo Nordisk
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Dennis Ungan
Principal Scientist,
Novartis
Dimitri Sideris
Senior Scientist,
AstraZeneca
Dominic Hildebrand
Senior Director, Head of Analytical Development and Clinical QC,
Bayer
Elaine Dymond
Vice President, Global Quality,
Autolus
Elisabetta Bianchi
Director of Discovery Chemistry,
Curium Pharma
Enda Kenny
Chief Executive Officer,
Rose Pharma Inc
Fabio Centola
CQA Manager,
Merck & Cie KmG
Federico Riccardi Sirtori
Director, Head of NBE-DMPK Innovative Bioanalytics,
Merck & Cie KmG
Felix Wojcik
Principal Scientist,
Novo Nordisk
Fernando Albericio
Professor,
University of KwaZulu-Natal
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Hans Melo
Chief Executive Officer,
Menten AI
James Legg
Chief Scientific Officer,
Cytospire Therapeutics
Jared Jackson
Scientist I,
Ultragenyx Gene Therapy
John Bridgeman
CSO,
Immunokey
John Wade
Professor and Head of Peptide & Protein Chemistry,
The Florey Institute
Joost Uitdehaag
Head of Biology,
Crossfire Oncology B.V.
Kai Hilpert
Professor,
City St George's, University of London
Kurt Pike
Senior Director, External Innovation,
Janssen R&D, LLC
Livija Deban
Chief Scientific Officer,
Prokarium
Lolke De Haan
Vice President of Toxicology,
ADC Therapeutics (UK) Ltd
Lukas Leder
Senior Principal Scientist,
Novartis
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Mariolina Salio
Director Experimental Immunology,
Immunocore
Mark Eccleston
Chief Executive Officer,
ValiRx
Matthew Burke
Senior Scientist,
UCB
Michael Delaney
Senior Principal Scientist,
Novo Nordisk
Michelle Barnard
Director of Research,
ValiRx
Miguel Gaspar
Senior Director,
Astrazeneca
Mihaela Bozic
Scientist,
T-Therapeutics Ltd
Mikhail Kuravsky
Principal Scientist,
UCB
Mohammad Arastoo
Research Fellow,
University of Aberdeen
Ni Huang
Associate Director,
T-Therapeutics Ltd
Paul Reid
Chief Executive Officer,
Celtic Biotech
Ranganath Gopalakrishnan
Director,
AstraZeneca
Ricardo Carreira
Associate Director,
Immunocore
Robert Wilkinson
Vice President, Head of Oncology Research,
Immunocore
Saif Shubber
Associate Director,
Bicycle Therapeutics
Sandor Batkai
Freelance Consultant,
Cardior Pharmaceuticals
Sheeba Irshad
Professor in Cancer Immunology,
Kings College London
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sridhar Neelamraju
Associate Principal Informatician,
AstraZeneca
Sritama Bose
Associate Director of Chemistry,
Orfonyx Bio
Steve Hood
Senior Director,
GSK
Steven Rust
Senior Director Protein Engineering,
Gilead Sciences
Sudhir Agrawal
Founder and President,
ARNAY Sciences
Sunay Chankeshwara
Associate Principal Scientist,
Astrazeneca
Tomasz Witkos
Associate Director,
AstraZeneca
Trevor Wattam
Associate Director,
GSK
Victoria Brentville
Principal Scientist,
Scancell
Vivek Verma
Lecturer,
Imperial College London
Xinxin Gao
Senior Principal Scientific Manager,
Genentech
Yi-Ru Yu
Lead Scientist,
Pilatus Biosciences SA
GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

The Start-up Zone

The start-up zone provides a unique opportunity for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals. 

Designed for start-ups from across the biologics space, its the perfect platform to share your business plans and showcase cutting-edge therapies and innovative platform technologies.

Find out how to get started with your application, below.

Start-up Zone Image-1

Getting There

QEII
Broad Sanctuary, London SW1P 3EE

Located in the heart of Westminster, the Queen Elizabeth II Centre is just minutes from three major Underground lines, Jubilee, District, and Circle via nearby Westminster and St. James’s Park stations. The venue is within walking distance of key National Rail stations including Charing Cross, Victoria, and Waterloo, and offers excellent connections to London City and Gatwick airports. Set opposite Westminster Abbey and close to Parliament Square, the QEII Centre is ideally placed for both business and leisure visitors. While there is no public parking on-site, Blue Badge holders may park on the forecourt (by prior arrangement), with public parking available nearby. 

 

 

By Air  

London City Airport  The QEII Centre is easily accessible from London City Airport via the DLR. Take the DLR to Bank station, then transfer to the Circle or District line to Westminster. From Westminster station, it's a short 5-minute walk to the Centre. The journey costs between £3.50 and £5, depending on time and payment method. Alternatively, a taxi will take approximately 30 minutes and cost around £40–£45, depending on traffic. 

 

London Gatwick Airport  Take a Thameslink train from Gatwick to London Bridge (around 35 minutes), then transfer to the Jubilee line for Waterloo or Westminster. From Westminster station, it’s just a 5-minute walk to the QEII Centre. A taxi from Gatwick typically takes 60–90 minutes, with fares ranging from £65 to £85. 

 

Heathrow Airport – From Heathrow Airport, take the Elizabeth Line to Bond Street, then transfer to the Jubilee line to Westminster Station, which is a short 5 minute walk to the QEII Centre. The Piccadilly Line to Hammersmith switching to the District Line to Westminster is also another route which can be taken. A taxi from Heathrow to the venue takes around 45 – 60 minutes and can cost from £40 - £80.  

 

 

By Underground and Bus 

St. James’s Park is just a four-minute walk from the Queen Elizabeth II Centre and is served by the Circle and District lines. However, please note that this station does not offer step-free access, which may be important for those with mobility needs. Alternatively, Westminster Station is approximately a five-minute walk away and provides access to the Circle, District, and Jubilee lines. Westminster is a step-free station and offers accessible routes suitable for passengers with limited mobility. 

 

If arriving via Westminster Station, exit through Exit 6. This leads into an underground tunnel that emerges near Parliament Square. Once at street level, continue onto Whitehall, then turn left into Parliament Square. From there, cross the road and turn right onto Broad Sanctuary. The Queen Elizabeth II Centre will be on your right, directly opposite Westminster Abbey. 

 

For those travelling by bus, routes 11, 88, and 148 all serve the area around Parliament Square. These buses will drop passengers either directly outside Westminster Abbey or within close proximity to it, offering convenient access to the venue. 

 

 

By Rail  

The nearest National Rail station is Charing Cross, approximately a 12-minute walk from the QEII Centre. Victoria Station is also within walking distance, taking around 14 minutes on foot, while Waterloo Station is slightly further, at about an 18-minute walk. All three stations offer excellent transport links across London and beyond. 

 

 

By Car  

Leave the A4 at the Lancaster Place/Aldwych exit and continue onto the Strand. At Trafalgar Square, take the third exit onto Northumberland Avenue. Follow it to Victoria Embankment, then turn right. Continue briefly, then turn left onto Bridge Street. At Parliament Square, bear left onto Broad Sanctuary. The Queen Elizabeth II Centre will be on your right, opposite Westminster Abbey. Nearby public parking is available.  

 

 

Parking 

The QEII Centre does not offer public car parking facilities. However, Blue Badge holders are permitted to park on the Centre’s forecourt free of charge, subject to availability. Visitors are advised to call ahead on +44 20 7798 4000 to confirm access. Disabled passengers arriving by taxi or other vehicles may also be dropped off on the forecourt. For other visitors, JustPark offers nearby parking spaces, with prices starting from £3.30. Please see here.  

 

 

More information on Accommodation will be coming soon.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2026, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of NextGen Biomed 2026 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

2025 Sponsors Include

Register Now

Be part of the new wave of Biomed R&D innovation,

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients